Shopping Cart
- Remove All
- Your shopping cart is currently empty
Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor that prevents the degradation of cyclic guanosine monophosphate (cGMP) with an IC50 of 3.6 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $683 | 8-10 weeks | |
50 mg | $888 | 8-10 weeks | |
100 mg | $1,340 | 8-10 weeks |
Description | Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor that prevents the degradation of cyclic guanosine monophosphate (cGMP) with an IC50 of 3.6 nM. |
Targets&IC50 | PDE1A:9.1 μM, PDE5A:3.6 nM |
In vitro | The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity.Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed.?This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. |
In vivo | Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. |
Alias | UK 369003-26 |
Molecular Weight | 677.79 |
Formula | C29H39N7O8S2 |
Cas No. | 334827-98-4 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.